Literature DB >> 26344059

Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue.

Marta Marquié1,2,3, Marc D Normandin4, Charles R Vanderburg1,2,5, Isabel M Costantino1,2, Elizabeth A Bien1,2,5, Lisa G Rycyna1,2,5, William E Klunk6, Chester A Mathis7, Milos D Ikonomovic8,9, Manik L Debnath6, Neil Vasdev4, Bradford C Dickerson2, Stephen N Gomperts1,2, John H Growdon2, Keith A Johnson2, Matthew P Frosch1,2,10, Bradley T Hyman1,2,5, Teresa Gómez-Isla1,2.   

Abstract

OBJECTIVE: To examine region- and substrate-specific autoradiographic and in vitro binding patterns of positron emission tomography tracer [F-18]-AV-1451 (previously known as T807), tailored to allow in vivo detection of paired helical filament-tau-containing lesions, and to determine whether there is off-target binding to other amyloid/non-amyloid proteins.
METHODS: We applied [F-18]-AV-1451 phosphor screen autoradiography, [F-18]-AV-1451 nuclear emulsion autoradiography, and [H-3]-AV-1451 in vitro binding assays to the study of postmortem samples from patients with a definite pathological diagnosis of Alzheimer disease, frontotemporal lobar degeneration-tau, frontotemporal lobar degeneration-transactive response DNA binding protein 43 (TDP-43), progressive supranuclear palsy, corticobasal degeneration, dementia with Lewy bodies, multiple system atrophy, cerebral amyloid angiopathy and elderly controls free of pathology.
RESULTS: Our data suggest that [F-18]-AV-1451 strongly binds to tau lesions primarily made of paired helical filaments in Alzheimer brains (eg, intraneuronal and extraneuronal tangles and dystrophic neurites), but does not seem to bind to a significant extent to neuronal and glial inclusions mainly composed of straight tau filaments in non-Alzheimer tauopathy brains or to lesions containing β-amyloid, α-synuclein, or TDP-43. [F-18]-AV-1451 off-target binding to neuromelanin- and melanin-containing cells and, to a lesser extent, to brain hemorrhagic lesions was identified.
INTERPRETATION: Our data suggest that [F-18]-AV-1451 holds promise as a surrogate marker for the detection of brain tau pathology in the form of tangles and paired helical filament-tau-containing neurites in Alzheimer brains but also point to its relatively lower affinity for lesions primarily made of straight tau filaments in non-Alzheimer tauopathy cases and to the existence of some [F-18]-AV-1451 off-target binding. These findings provide important insights for interpreting in vivo patterns of [F-18]-AV-1451 retention.
© 2015 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26344059      PMCID: PMC4900162          DOI: 10.1002/ana.24517

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  23 in total

1.  Twenty-first century brain banking. Processing brains for research: the Columbia University methods.

Authors:  Jean Paul G Vonsattel; Maria Pilar Del Amaya; Christian E Keller
Journal:  Acta Neuropathol       Date:  2007-11-06       Impact factor: 17.088

2.  Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807.

Authors:  David T Chien; Shadfar Bahri; A Katrin Szardenings; Joseph C Walsh; Fanrong Mu; Min-Ying Su; William R Shankle; Arkadij Elizarov; Hartmuth C Kolb
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

3.  [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease.

Authors:  Chun-Fang Xia; Janna Arteaga; Gang Chen; Umesh Gangadharmath; Luis F Gomez; Dhanalakshmi Kasi; Chung Lam; Qianwa Liang; Changhui Liu; Vani P Mocharla; Fanrong Mu; Anjana Sinha; Helen Su; A Katrin Szardenings; Joseph C Walsh; Eric Wang; Chul Yu; Wei Zhang; Tieming Zhao; Hartmuth C Kolb
Journal:  Alzheimers Dement       Date:  2013-02-12       Impact factor: 21.566

4.  Fluorine-18 uptake and localization in soft tissue deposits of osteogenic sarcoma in rat and man.

Authors:  D H Woodbury; W H Beierwaltes
Journal:  J Nucl Med       Date:  1967-09       Impact factor: 10.057

5.  Glial and neuronal tau pathology in tauopathies: characterization of disease-specific phenotypes and tau pathology progression.

Authors:  Isidre Ferrer; Irene López-González; Margarita Carmona; Laura Arregui; Esther Dalfó; Benjamin Torrejón-Escribano; Roberta Diehl; Gabor G Kovacs
Journal:  J Neuropathol Exp Neurol       Date:  2014-01       Impact factor: 3.685

6.  Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration.

Authors:  Nigel J Cairns; Eileen H Bigio; Ian R A Mackenzie; Manuela Neumann; Virginia M-Y Lee; Kimmo J Hatanpaa; Charles L White; Julie A Schneider; Lea Tenenholz Grinberg; Glenda Halliday; Charles Duyckaerts; James S Lowe; Ida E Holm; Markus Tolnay; Koichi Okamoto; Hideaki Yokoo; Shigeo Murayama; John Woulfe; David G Munoz; Dennis W Dickson; Paul G Ince; John Q Trojanowski; David M A Mann
Journal:  Acta Neuropathol       Date:  2007-06-20       Impact factor: 17.088

Review 7.  The neuropathological spectrum of neurodegenerative tauopathies.

Authors:  Markus Tolnay; Alphonse Probst
Journal:  IUBMB Life       Date:  2003-06       Impact factor: 3.885

8.  The pathology of superficial siderosis of the central nervous system.

Authors:  Arnulf H Koeppen; Susan C Michael; Danhong Li; Zewu Chen; Matthew J Cusack; Walter M Gibson; Simone V Petrocine; Jiang Qian
Journal:  Acta Neuropathol       Date:  2008-08-12       Impact factor: 17.088

9.  Second consensus statement on the diagnosis of multiple system atrophy.

Authors:  S Gilman; G K Wenning; P A Low; D J Brooks; C J Mathias; J Q Trojanowski; N W Wood; C Colosimo; A Dürr; C J Fowler; H Kaufmann; T Klockgether; A Lees; W Poewe; N Quinn; T Revesz; D Robertson; P Sandroni; K Seppi; M Vidailhet
Journal:  Neurology       Date:  2008-08-26       Impact factor: 9.910

Review 10.  Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias.

Authors:  Melissa E Murray; Naomi Kouri; Wen-Lang Lin; Clifford R Jack; Dennis W Dickson; Prashanthi Vemuri
Journal:  Alzheimers Res Ther       Date:  2014-01-02       Impact factor: 6.982

View more
  289 in total

Review 1.  Current Understanding of Neurodegenerative Diseases Associated With the Protein Tau.

Authors:  Keith A Josephs
Journal:  Mayo Clin Proc       Date:  2017-08       Impact factor: 7.616

2.  Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies.

Authors:  Maiko Ono; Naruhiko Sahara; Katsushi Kumata; Bin Ji; Ruiqing Ni; Shunsuke Koga; Dennis W Dickson; John Q Trojanowski; Virginia M-Y Lee; Mari Yoshida; Isao Hozumi; Yasumasa Yoshiyama; John C van Swieten; Agneta Nordberg; Tetsuya Suhara; Ming-Rong Zhang; Makoto Higuchi
Journal:  Brain       Date:  2017-03-01       Impact factor: 13.501

3.  Correlation of In Vivo [18F]Flortaucipir With Postmortem Alzheimer Disease Tau Pathology.

Authors:  Ruben Smith; Moa Wibom; Daria Pawlik; Elisabet Englund; Oskar Hansson
Journal:  JAMA Neurol       Date:  2019-03-01       Impact factor: 18.302

4.  [F-18]-AV-1451 binding correlates with postmortem neurofibrillary tangle Braak staging.

Authors:  Marta Marquié; Michael Siao Tick Chong; Alejandro Antón-Fernández; Eline E Verwer; Nil Sáez-Calveras; Avery C Meltzer; Prianca Ramanan; Ana C Amaral; Jose Gonzalez; Marc D Normandin; Matthew P Frosch; Teresa Gómez-Isla
Journal:  Acta Neuropathol       Date:  2017-06-13       Impact factor: 17.088

5.  Positron emission tomography imaging of tau pathology in progressive supranuclear palsy.

Authors:  Sarah Coakeley; Sang Soo Cho; Yuko Koshimori; Pablo Rusjan; Madeleine Harris; Christine Ghadery; Jinhee Kim; Anthony E Lang; Alan Wilson; Sylvain Houle; Antonio P Strafella
Journal:  J Cereb Blood Flow Metab       Date:  2016-12-22       Impact factor: 6.200

Review 6.  Future Directions in Imaging Neurodegeneration.

Authors:  Joseph C Masdeu
Journal:  Curr Neurol Neurosci Rep       Date:  2017-01       Impact factor: 5.081

7.  Tau Positron Emission Tomography Binding Is Not Elevated in HIV-Infected Individuals.

Authors:  Sarah A Cooley; Jeremy F Strain; Helen Beaumont; Anna H Boerwinkle; John Doyle; John C Morris; Tammie L Benzinger; Beau M Ances
Journal:  J Infect Dis       Date:  2019-06-05       Impact factor: 5.226

8.  Pharmacokinetic Evaluation of the Tau PET Radiotracer 18F-T807 (18F-AV-1451) in Human Subjects.

Authors:  Dustin W Wooten; Nicolas J Guehl; Eline E Verwer; Timothy M Shoup; Daniel L Yokell; Nevena Zubcevik; Neil Vasdev; Ross D Zafonte; Keith A Johnson; Georges El Fakhri; Marc D Normandin
Journal:  J Nucl Med       Date:  2016-09-22       Impact factor: 10.057

9.  Sensitivity-Specificity of Tau and Amyloid β Positron Emission Tomography in Frontotemporal Lobar Degeneration.

Authors:  Alma Ghirelli; Nirubol Tosakulwong; Stephen D Weigand; Heather M Clark; Farwa Ali; Hugo Botha; Joseph R Duffy; Rene L Utianski; Marina Buciuc; Melissa E Murray; Sydney A Labuzan; Anthony J Spychalla; Nha Trang Thu Pham; Christopher G Schwarz; Matthew L Senjem; Mary M Machulda; Matthew Baker; Rosa Rademakers; Massimo Filippi; Clifford R Jack; Val J Lowe; Joseph E Parisi; Dennis W Dickson; Keith A Josephs; Jennifer L Whitwell
Journal:  Ann Neurol       Date:  2020-09-12       Impact factor: 10.422

10.  Regional Tau Effects on Prospective Cognitive Change in Cognitively Normal Older Adults.

Authors:  Xi Chen; Kaitlin E Cassady; Jenna N Adams; Theresa M Harrison; Suzanne L Baker; William J Jagust
Journal:  J Neurosci       Date:  2020-11-20       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.